Drug intelligence / Profile preview

Lactobacillus paragasseri HM018

Development stage: Preclinical
Lead developer: Beijing Sanyuan Foods
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus paragasseri HM018 is a human breast milk-derived probiotic strain developed for the management of hyperlipidemia and related metabolic disorders. It functions by remodeling the gut microbiota, specifically reducing the Firmicutes/Bacteroidetes ratio and suppressing bile salt hydrolase-producing bacteria. This modulation leads to altered bile acid composition, promoting cholesterol excretion via the reverse cholesterol transport (RCT) and transintestinal cholesterol excretion (TICE) pathways. Additionally, HM018 regulates hepatic and intestinal gene expression, upregulating cholesterol efflux transporters (Abcg5/Abcg8) and apolipoprotein A-I (Apoa1), while downregulating inhibitors of insulin and growth hormone signaling (Socs2, Socs3, Cish), thereby improving lipid and glucose metabolism.

Other names: L. paragasseri HM018

Targets

SOCS2 (Suppressor of cytokine signaling 2)APOA1 (Apolipoprotein A-I)ABCG8 (ATP-binding cassette sub-family G member 8)SOCS3 (Suppressor of cytokine signaling 3)TRAF3IP2 (Interleukin 17 pathway adaptor protein Act1)ABCG5 (ATP-binding cassette sub-family G member 5)

Beyond the preview

Go deeper on Lactobacillus paragasseri HM018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus paragasseri HM018.

Explore the full profile